King Pharmaceuticals, Inc. CIA
Transcript of King Pharmaceuticals, Inc. CIA
![Page 1: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/1.jpg)
Attachment H
CORPORATE INTEGRITY AGREEMENT BETWEEN THE
OFFICE OF INSPECTOR GENERAL OF THE
DEPARTMENT OF HEALTH AND HUMAN SERVICES AND
K ~ N G PHARMACEUTICALS, INC.
King Pharmaceuticals, Inc., and its United States subsidiaries that manufacture or sell pharmaceutical products (collectively, "King") hereby enters into this Corporate Integrity Agreement (CIA) with the Office of Inspector General (OIG) of the United States Department of Health and Human Services (HHS) to promote compliance with the statutes, regulations, and written directives of Medicare, Medicaid, and all other Federal health care programs (as defined in 42 U.S.C. 5 1320a-7b(f)) in which King participates and the requirements of other government programs in which King participates (collectively, "Federal Health Care Programs") specified below in Section II.C.2 (Federal Health Care Program Requirements). Contemporaneously with this CIA, King is entering into a settlement agreement with the United States (Settlement Agreement), and this CIA is incorporated by reference into the Settlement Agreement. King also will enter into settlement agreements with various States, and King's agreement to this CIA is a condition precedent to those agreements.
Prior to the Effective Date of this CIA (as defined below), King established a voluntary compliance program which, as represented by King, includes, among other things, the appointment of a Corporate Compliance Officer, the development and dissemination of a Code of Conduct, the establishment of written policies and procedures, a Disclosure Program, screening measures for Ineligible Persons, review and disciplinary proceedings, regular training to Covered Persons concerning King's Code of Conduct and policies and procedures, and regular internal auditing.
Corporate Integrity Agreement King Pharmaceuticals, Inc.
![Page 2: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/2.jpg)
![Page 3: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/3.jpg)
![Page 4: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/4.jpg)
![Page 5: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/5.jpg)
![Page 6: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/6.jpg)
![Page 7: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/7.jpg)
![Page 8: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/8.jpg)
![Page 9: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/9.jpg)
![Page 10: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/10.jpg)
![Page 11: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/11.jpg)
![Page 12: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/12.jpg)
![Page 13: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/13.jpg)
![Page 14: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/14.jpg)
![Page 15: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/15.jpg)
![Page 16: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/16.jpg)
![Page 17: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/17.jpg)
![Page 18: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/18.jpg)
![Page 19: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/19.jpg)
![Page 20: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/20.jpg)
![Page 21: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/21.jpg)
![Page 22: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/22.jpg)
![Page 23: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/23.jpg)
![Page 24: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/24.jpg)
![Page 25: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/25.jpg)
![Page 26: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/26.jpg)
![Page 27: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/27.jpg)
![Page 28: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/28.jpg)
![Page 29: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/29.jpg)
![Page 30: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/30.jpg)
![Page 31: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/31.jpg)
![Page 32: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/32.jpg)
![Page 33: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/33.jpg)
![Page 34: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/34.jpg)
![Page 35: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/35.jpg)
![Page 36: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/36.jpg)
![Page 37: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/37.jpg)
![Page 38: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/38.jpg)
![Page 39: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/39.jpg)
![Page 40: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/40.jpg)
![Page 41: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/41.jpg)
![Page 42: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/42.jpg)
![Page 43: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/43.jpg)
![Page 44: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/44.jpg)
![Page 45: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/45.jpg)
![Page 46: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/46.jpg)
![Page 47: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/47.jpg)
![Page 48: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/48.jpg)
![Page 49: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/49.jpg)
![Page 50: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/50.jpg)
![Page 51: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/51.jpg)
![Page 52: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/52.jpg)
![Page 53: King Pharmaceuticals, Inc. CIA](https://reader036.fdocuments.us/reader036/viewer/2022071518/613c103b22e01a42d40e72b7/html5/thumbnails/53.jpg)